Sean Laaman
Stock Analyst at Morgan Stanley
(4.33)
# 348
Out of 5,245 analysts
32
Total ratings
58.33%
Success rate
19.82%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GENB Generate Biomedicines | Maintains: Overweight | $20 → $22 | $14.53 | +51.41% | 2 | May 14, 2026 | |
| IRON Disc Medicine | Maintains: Overweight | $75 → $80 | $66.82 | +19.72% | 4 | May 14, 2026 | |
| CERT Certara | Maintains: Equal-Weight | $11 → $10 | $5.24 | +90.84% | 3 | May 12, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $49 → $50 | $50.15 | -0.30% | 7 | May 6, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Equal-Weight | $217 → $242 | $235.97 | +2.56% | 5 | May 5, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Overweight | $32 | $10.91 | +193.31% | 1 | Mar 2, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $96 → $98 | $69.12 | +41.78% | 2 | Feb 25, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Overweight | $20 | $8.55 | +133.92% | 1 | Dec 5, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Overweight | $34 | $28.75 | +18.26% | 1 | Nov 21, 2025 | |
| RMD ResMed | Maintains: Overweight | $298 → $304 | $208.05 | +46.12% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $383 | $310.25 | +23.45% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $3 → $1.5 | $2.21 | -32.13% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $67 | $68.32 | -1.93% | 1 | Feb 14, 2025 |
Generate Biomedicines
May 14, 2026
Maintains: Overweight
Price Target: $20 → $22
Current: $14.53
Upside: +51.41%
Disc Medicine
May 14, 2026
Maintains: Overweight
Price Target: $75 → $80
Current: $66.82
Upside: +19.72%
Certara
May 12, 2026
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $5.24
Upside: +90.84%
Exelixis
May 6, 2026
Maintains: Equal-Weight
Price Target: $49 → $50
Current: $50.15
Upside: -0.30%
Axsome Therapeutics
May 5, 2026
Maintains: Equal-Weight
Price Target: $217 → $242
Current: $235.97
Upside: +2.56%
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $32
Current: $10.91
Upside: +193.31%
BridgeBio Pharma
Feb 25, 2026
Maintains: Overweight
Price Target: $96 → $98
Current: $69.12
Upside: +41.78%
BridgeBio Oncology Therapeutics
Dec 5, 2025
Initiates: Overweight
Price Target: $20
Current: $8.55
Upside: +133.92%
MapLight Therapeutics
Nov 21, 2025
Initiates: Overweight
Price Target: $34
Current: $28.75
Upside: +18.26%
ResMed
Oct 21, 2025
Maintains: Overweight
Price Target: $298 → $304
Current: $208.05
Upside: +46.12%
Oct 20, 2025
Maintains: Overweight
Price Target: $350 → $383
Current: $310.25
Upside: +23.45%
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $2.21
Upside: -32.13%
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $68.32
Upside: -1.93%